Dogwood Therapeutics (NASDAQ:DWTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Dogwood Therapeutics (NASDAQ:DWTX) in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a $12.00 target price on the stock.

Dogwood Therapeutics Trading Down 2.9%

Shares of NASDAQ DWTX opened at $1.34 on Monday. The firm’s 50-day moving average price is $2.40 and its 200-day moving average price is $3.98. The stock has a market capitalization of $44.76 million, a price-to-earnings ratio of -0.07 and a beta of 2.05. Dogwood Therapeutics has a 12-month low of $1.28 and a 12-month high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.96. On average, equities analysts predict that Dogwood Therapeutics will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.